Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in R/R MCL patients and preclinical models suggest a potential synergistic effect of dual BTK and BCL2 inhibition. Ibrutinib in association with venetoclax was successfully investigated in a phase II trial.
Fabbri, A., Cencini, E., Congiu, A.G., Miglino, M., Rigacci, L., Bocchia, M. (2020). Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series. AMERICAN JOURNAL OF BLOOD RESEARCH, 10(6), 355-359.
Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series
Cencini, Emanuele;Bocchia, Monica
2020-01-01
Abstract
Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in R/R MCL patients and preclinical models suggest a potential synergistic effect of dual BTK and BCL2 inhibition. Ibrutinib in association with venetoclax was successfully investigated in a phase II trial.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Ibrutinib in association-Fabbri-2020.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
231.72 kB
Formato
Adobe PDF
|
231.72 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1147012